Axogen was recently the focus of an article written by Seeking Alpha author Equity Options Guru, who noted the regenerative medicine company’s advancing product line and strong third-quarter financials in his positive opine.
To read the full article visit: http://seekingalpha.com/article/1822032
Focused on developing and bringing to market technologies for peripheral nerve generation and reconstruction, Axogen has created a pipeline of products designed to improve the standard of care for patients with peripheral nerve injuries:
• Avance® Nerve Graft – A peripheral nerve allograft for the reconstruction of peripheral nerve discontinuities (severed nerve gaps) in order to guide and support axonal regeneration across a nerve gap caused by traumatic injury or surgical intervention.
• AxoGuard® Nerve Connector – A coaptation aid that allows for the close approximation of severed nerves. The purpose is to align and connect nerves with less than a 5mm gap between the severed nerve ends.
• AxoGuard® Nerve Protector – An implant that provides protection for peripheral nerves. Its primary purpose is to protect and isolate the nerve during the healing process after surgery.
As the author notes by writing, “The advances that the company has made with its technology have translated well to the company’s earnings as shown in the third-quarter report,” Axogen achieved sales growth of 50 percent in the quarter and has adequate cash flow to continue operations.
“As with all small-cap companies, investors should pay attention to the company’s available cash as dilution is always a concern. Based on the company’s current cash on hand, dilution risk appears minimal going forward. AxoGen ended the quarter with $22.6 million in cash and cash equivalents. This includes the proceeds from the secondary that the company completed in August. Given that the company’s monthly burn rate is approximately $700,000, the $22.6 million should be enough to fund the company for at least the next several years. As revenues continue to grow with additional product awareness, the need for additional cash should become even less,” Equity Stock Guru writes.
Among other highlights, the article discusses the Axogen trading activity (the stock has surged 60 percent in the past year) and points out that the company has provided a higher ROI for investors than both the broader market and the biotech/healthcare industries.
For more information, visit www.axogeninc.com
Let us hear your thoughts below:
